Bullfrog AI (BFRG)

Executive Summary

Bullfrog AI (BFRG) is an early-stage biotechnology company leveraging its proprietary, explainable AI platform, bfLEAP™, to transform drug discovery and development. The platform is designed to de-risk clinical programs by harmonizing and analyzing complex biomedical data (bfPREP™), enabling faster, more cost-effective therapeutic development. Bullfrog AI operates a dual business model: advancing an in-licensed pipeline of novel therapies in oncology and metabolic diseases, while also offering its AI-driven analytics as a service to biopharma partners. This approach positions the company to generate near-term revenue through partnerships while building long-term value from its own drug candidates. As a public company with a small market cap (~$13M), Bullfrog AI represents a high-risk, high-potential opportunity in the AI-powered drug discovery space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new biopharma partnership for bfLEAP platform60% success
• Q3 2026Update on lead in-licensed oncology program (preclinical data)50% success
• Q4 2026Potential grant or non-dilutive funding award40% success